Fatima Bangura
Family · Collingdale, PANPI 1801219472
Payments from drug & device makers
Across 209 payments — averaging $25.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$947
- Novo Nordisk$651
- Bayer$476
- Teva Pharmaceuticals USA, Inc.$250
- Lilly USA, LLC$246
- plus $1K from 16 others
What the payments were for
- Food & beverage$5,24298%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 71 | $1,273 |
| GSK | 29 | $947 |
| Novo Nordisk | 22 | $651 |
| Bayer | 14 | $476 |
| Teva Pharmaceuticals USA, Inc. | 15 | $250 |
| Lilly USA, LLC | 12 | $246 |
| Neurocrine Biosciences, Inc. | 7 | $238 |
| Boehringer Ingelheim | 5 | $196 |
| Braeburn Inc. | 3 | $166 |
| Sanofi-aventis U.S. LLC | 3 | $154 |
| Astellas Pharma US Inc | 3 | $144 |
| Pfizer | 1 | $117 |
| Novartis | 7 | $109 |
| Exact Sciences | 5 | $108 |
| AstraZeneca | 4 | $67 |
| Medtronic | 1 | $60 |
| E.r. Squibb & Sons, L.L.C. | 2 | $49 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Shield Therapeutics Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,342 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 133 | $143,363 |
| JardianceEmpagliflozin | 141 | $115,167 |
| FarxigaDapagliflozin Propanediol | 134 | $108,376 |
| EliquisApixaban | 125 | $86,319 |
| TrulicityDulaglutide | 58 | $71,092 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 92 | $64,705 |
| VraylarCariprazine Hcl | 23 | $30,962 |
| JanuviaSitagliptin Phosphate | 29 | $24,691 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $18,254 |
| EntrestoSacubitril/Valsartan | 20 | $17,458 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 484 | $13,330 |
| LinzessLinaclotide | 22 | $11,309 |
| Esomeprazole Magnesium | 53 | $9,664 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $7,790 |
| RestasisCyclosporine | 12 | $7,549 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $651 | $143,363133 claims |
| Boehringer IngelheimJardiance | $196 | $115,167141 claims |
| AstraZenecaFarxiga, Symbicort | $67 | $111,423148 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $947 | $90,749142 claims |
| PfizerEliquis | $117 | $86,319125 claims |
| Lilly USA, LLCTrulicity | $246 | $71,09258 claims |
| AbbVieVraylar, Linzess, Restasis | $1,273 | $49,82057 claims |
| NovartisEntresto | $109 | $17,45820 claims |
| Astellas Pharma US IncMyrbetriq | $144 | $6,55711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.
Other family in Collingdale
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.